While FoxO1 is hailed as a potential therapeutic target for metabolic disease (28, 82), our data suggest that pharmacological inhibition of FoxO1 activity in inflammatory macrophages could curb abnormal macrophage activation and mitigate tissue inflammation to improve insulin sensitivity and hepatic metabolism for preventing the development of NASH in metabolic disease. This evidence concerns the gene FOXO1 and metabolic disease.